Aqur Biosciences, Inc. — SEC Form D Filing

Aqur Biosciences, Inc. filed an SEC Form D on September 18, 2026, reporting $1.50M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 18, 2026
Amount reported
$1.50M
Industry
Biotechnology
Website
https://aqurbiosciences.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: NEVADA

Problem

Hypercholesterolemia and cardiovascular disease are conditions that limit human potential and require improved treatment options.

Solution

Aqur Biosciences is developing AQR-008, a differentiated PCSK9-pathway modulator, as an effective, user-friendly, and accessible therapeutic candidate for the treatment of hypercholesterolemia.

Why now

Advances in bioscience and drug development, particularly in understanding pathways like PCSK9, allow for the creation of more targeted and effective treatments for widespread cardiovascular diseases.

Verdict

Investors backed this biotechnology play for its established target pathway and the promise of a differentiated candidate, not for its early-stage clinical data. This cleared because it tapped into proven large-market disease indications where premium pricing is accepted for innovation. Implicitly, investors were betting on the de-risking impact of a known mechanism-of-action and a clear unmet need. Upside was limited by the long, capital-intensive development timeline inherent in drug discovery, alongside the significant clinical trial risks and the competitive landscape for PCSK9 modulation.

Source: SEC EDGAR Form D filing